Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2012

Published : July 2012
No. of Pages : 126

Price:

Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ''Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2012'', provides an overview of the Cytomegalovirus (HHV-5) Infections therapeutic pipeline. This report provides information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections. ''Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2012'' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cytomegalovirus (HHV-5) Infections.
- A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Cytomegalovirus (HHV-5) Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cytomegalovirus (HHV-5) Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Cytomegalovirus (HHV-5) Infections 9
Cytomegalovirus (HHV-5) Infections Therapeutics under Development by Companies 11
Cytomegalovirus (HHV-5) Infections Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Cytomegalovirus (HHV-5) Infections Therapeutics – Products under Development by Companies 20
Cytomegalovirus (HHV-5) Infections Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Cytomegalovirus (HHV-5) Infections Therapeutics Development 22
Vical Incorporated 22
GlaxoSmithKline plc 23
Novartis AG 24
Astellas Pharma Inc. 25
Alfacell Corporation 26
Summit Corporation plc 27
Clavis Pharma ASA 28
Nutri Pharma ASA 29
Altor BioScience Corporation 30
AiCuris GmbH & Co. KG 31
Cell Medica Limited 32
Chimerix, Inc. 33
Theraclone Sciences, Inc. 34
4-Antibody AG 35
Variation Biotechnologies, Inc. 36
Vakzine Projekt Management GmbH 37
Cytomegalovirus (HHV-5) Infections – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 45
Camvia - Drug Profile 45
CyMVectin - Drug Profile 47
CMX001 - Drug Profile 48
TCN-202 - Drug Profile 49
ASP0113 - Drug Profile 50
Antiviral TCR-Ck - Drug Profile 51
Antiviral TCR-Ig - Drug Profile 52
4Ab-028 - Drug Profile 53
AVX601 - Drug Profile 54
CP-4018 - Drug Profile 56
VPM2001 - Drug Profile 57
CMV-Specific T-Cells + Ganciclovir + Valganciclovir + Foscarnet - Drug Profile 58
CMV-Specific Cytotoxic T Lymphocytes - Drug Profile 61
Donor-Derived CMV-pp65 Peptide-Specific T Cells - Drug Profile 63
AIC246 - Drug Profile 65
CMVpp65-A*0201 Peptide Vaccine - Drug Profile 66
Artesunate - Drug Profile 67
Cytotoxic T-Lymphocytes - Drug Profile 68
CMV Glycoprotein B Vaccine - Drug Profile 70
CMV gB + MF59 - Drug Profile 71
CMV-Specific T-cells - Drug Profile 73
Cytomegalovirus Specific Cytotoxic T Lymphocytes - Drug Profile 74
CMV Specific CTL - Drug Profile 76
GSK-1492903A - Drug Profile 77
Cytomegalovirus gB/MF59 Vaccine + MF-59 - Drug Profile 78
Cytotect - Drug Profile 79
Antiviral Program - Drug Profile 80
Valganciclovir - Drug Profile 81
Live Attenuated Human Cytomegalovirus (HCMV) Vaccine - Drug Profile 83
CMV Specific T Cell Donor Lymphocyte - Drug Profile 84
VCL CT02 pDNA Vaccine + Towne CMV Vaccine - Drug Profile 85
PADRE-CMV Fusion Peptide Vaccine + Tetanus-CMV Fusion Peptide Vaccine + Agatolimod Sodium - Drug Profile 87
PADRE-CMV Fusion Peptide Vaccine + Tetanus-CMV Fusion Peptide Vaccine - Drug Profile 89
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile 91
RBT 301 - Drug Profile 93
Valganciclovir - Drug Profile 94
Ganciclovir + Valganciclovir - Drug Profile 95
CMV Vaccine - Drug Profile 96
CMV Hyperimmune Globulin - Drug Profile 97
CD4 + CD8 T Cells - Drug Profile 98
P31 - Drug Profile 99
Recombinant Amphinase 2 - Drug Profile 100
CMV PP65-Specific T-Cells - Drug Profile 102
Cytomegalovirus (HHV-5) Infections Therapeutics – Drug Profile Updates 103
Cytomegalovirus (HHV-5) Infections Therapeutics – Discontinued Products 112
Cytomegalovirus (HHV-5) Infections Therapeutics - Dormant Products 113
Cytomegalovirus (HHV-5) Infections – Product Development Milestones 114
Featured News & Press Releases 114
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 123
Disclaimer 123

List of Tables
Number of Products Under Development for Cytomegalovirus (HHV-5) Infections, H2 2012 12
Products under Development for Cytomegalovirus (HHV-5) Infections – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Development by Companies, H2 2012 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
Vical Incorporated, H2 2012 25
GlaxoSmithKline plc, H2 2012 26
Novartis AG, H2 2012 27
Astellas Pharma Inc., H2 2012 28
Alfacell Corporation, H2 2012 29
Summit Corporation plc, H2 2012 30
Clavis Pharma ASA, H2 2012 31
Nutri Pharma ASA, H2 2012 32
Altor BioScience Corporation, H2 2012 33
AiCuris GmbH & Co. KG, H2 2012 34
Cell Medica Limited, H2 2012 35
Chimerix, Inc., H2 2012 36
Theraclone Sciences, Inc., H2 2012 37
4-Antibody AG, H2 2012 38
Variation Biotechnologies, Inc., H2 2012 39
Vakzine Projekt Management GmbH, H2 2012 40
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Stage and Molecule Type, H2 2012 47
Cytomegalovirus (HHV-5) Infections Therapeutics – Drug Profile Updates 106
Cytomegalovirus (HHV-5) Infections Therapeutics – Discontinued Products 115
Cytomegalovirus (HHV-5) Infections Therapeutics – Dormant Products 116

List of Figures
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2012 12
Products under Development for Cytomegalovirus (HHV-5) Infections – Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Discovery and Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Route of Administration, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Molecule Type, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 46

Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2012

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: